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The World Health Organization recommends artemisinin-based combination therapies (ACTs) for the treatment of uncomplicated
falciparum malaria in the second and third trimesters of pregnancy. We conducted a meta-analysis to compare efﬁcacy, safety and
tolerability of ACTs versus quinine and other non-ACT antimalarials. The median PCR-adjusted failure rate by days 28 to 63 in the
non-ACT group was 6 (range 0–37) per 100 women, lower in the ACT group overall (pooled risk ratio [PRR] random effects, 0.41;
95% conﬁdence interval [CI], 0.16–1.05; 6 trials), and signiﬁcantly lower compared with oral quinine (PRR, 0.20; 95% CI, 0.08–0.49;
4 trials). There were no differences in fetal deaths and congenital abnormalities. Compared with quinine, artemisinin-based
combinations therapies were associated with less tinnitus (PRR, 0.19; 95% CI, 0.03–1.11; 4 studies), dizziness (PRR, 0.64; 95% CI,
0.44–0.93; 3 trials), and vomiting (PRR, 0.33; 95% CI, 0.15–0.73; 3 trials). Artemisinin-based combination therapies are better than
quinine in the second and third trimesters; their use should be encouraged among health workers.
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Malaria is a potentially dangerous infection during pregnancy
and can lead to maternal anemia, miscarriage, stillbirth, or in-
fant low birth weight [1]. Since 2006, the World Health Orga-
nization has recommended the use of an artemisinin-based
combination therapy (ACT) for the treatment of uncomplicated
falciparum malaria in the second and third trimester of preg-
nancy [2, 3].By 2013, ACTs had been adopted as national policy
for ﬁrst-line treatment in 79 of 88 countries where Plasmodium
falciparum is endemic [4]; however, it has not always been clear
whether this policy is also applicable to treatment of pregnant
women in the second and third trimester. In countries where the
policy has been adopted, many health workers continue to pro-
vide oral quinine, the drug recommended for treatment in the
ﬁrst trimester [5]. Quinine is associated with low adherence
because it has to be taken 3 times per day for 7 days and is asso-
ciated with cinchonism, characterized by tinnitus, hearing im-
pairment, postural hypotension, and dizziness [6]. By contrast,
ACTs are administered once or twice daily for only 3 days, and
they are better tolerated than quinine. Over the past 2 decades,
several studies have compared the efﬁcacy and safety of ACTs to
quinine and other non-ACTs in the second and third trimester
[7–15], but individual studies often lack the power to draw de-
ﬁnitive conclusions. A Cochrane review examining maternal
treatment response, fetal outcomes, and drug safety of drug reg-
imens for uncomplicated falciparum malaria considered each
drug combination compared with the control drug as reported
in studies, but it did not evaluate ACTs as a group compared
with non-ACTs [16]. We conducted a meta-analysis of random-
ized controlled trials (RCTs) to compare the efﬁcacy, safety, and
tolerance of ACTs to quinine and other non-ACT antimalarials
for the case management of uncomplicated falciparum malaria
in the second and third trimester of pregnancy to provide pol-
icymakers with the evidence needed to improve adherence
among health providers to the current policy on treatment
with ACTs.
METHODS
Search Strategy
We searched the Malaria in Pregnancy Library up to May 2015
[17, 18] to identify all trials that compared the efﬁcacy and safety
of ACTs with other antimalarials with no restrictions to time or
geographic location. The Malaria in Pregnancy Library (http://
library.mip-consortium.org) is a comprehensive bibliographic
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database created by the Malaria in Pregnancy Consortium that
is updated every 4 months using a standardized protocol to
search over 40 sources, including PubMed, Web of Knowledge,
and Google Scholar. Languages other than English were not ex-
cluded a priori. The search followed the Preferred Reporting
Items for Systematic Reviews and Meta-Analyses (PRISMA)
statement guidelines [19]; no prior protocol for the meta-
analysis was developed. The following search terms were used:
artemether OR artesunate OR artemisinin OR dihydroartemisi-
nin OR ACT. No search terms were needed for malaria or preg-
nancy because the malaria in pregnancy library already screens
for these terms. The references of retrieved articles were exam-
ined to identify additional studies.
Selection Criteria
A ﬁrst screening was conducted based on title and abstracts;
the remaining references were reviewed by 2 authors (R.J.B.
and M.B.), and studies were included if they met the following
inclusion criteria: (1) RCT in humans comparing oral treat-
ment with ACTs vs non-ACTs; (2) inclusion of pregnant
women in their second and/or third trimester with uncompli-
cated falciparum malaria; and (3) availability of data to assess
the efﬁcacy and safety per treatment arm. Studies or study arms
that contained monotherapy of artemisinin derivatives or an-
timalarials or combination antimalarials that are currently no
longer considered or are contraindicated for treatment of
malaria in pregnancy (eg, sulfadoxine-pyrimethamine [SP]
alone and chlorproguanil-dapsone) were excluded. Discrep-
ancies between reviewers were resolved through discussion
until consensus was reached.
Quality Assessment
The same authors (R.J.B. and M.B.) assessed the quality of the
included studies using the Cochrane Collaboration’s tool for as-
sessing the risk of bias among randomized trials [20]. Quality
was classiﬁed as “low” (high risk of bias), “high” (low risk of bias),
or “unclear” (Supplementary 1, Tables 1.1 and 1.2). Details of
the quality criteria used are included in Supplementary 1.
Data Extraction
Data extraction was undertaken independently by 2 authors
(R.J.B. andM.B.) using spreadsheets. We extracted the following
general information: author, year of publication, geographic lo-
cation, population, details of treatment regimens used, and
number of women treated per arm, and study characteristics
such as mean age, gestational age, fever, bodyweight, gravidity,
and parasite density at the time of enrollment. To assess efﬁca-
cy, we extracted information on treatment efﬁcacy outcomes
based on the polymerase chain reaction (PCR)-adjusted failure
rate by day 28, 42, or 63, parasite and fever clearance, mean
birth weight, low birth weight, and mean gestational age. To as-
sess safety, we extracted information on preterm births (<37
weeks), congenital malformations, stillbirths, and miscarriage.
To assess tolerability, information on reported side-effects was
extracted, with special reference to side-effects commonly asso-
ciated with quinine, such as tinnitus, dizziness, vomiting, and
hypoglycemia [6]. Any discrepancies were resolved by discus-
sion until consensus was reached.
Outcomes
The primary outcome for the efﬁcacy analysis was the PCR-ad-
justed failure rate by day 28 to day 63 (whichever was reported
latest). Secondary outcomes included mean birth weight, prev-
alence of low birth weight, mean gestational age, and prevalence
of prematurity. The outcomes for the safety analysis were prev-
alence of congenital abnormalities, stillbirth, and miscarriage.
We combined the outcomes of miscarriage and stillbirths into
fetal loss because the number of women enrolled before 28
weeks gestation and at risk of miscarriage was not routinely re-
ported. To assess tolerability, we assessed the prevalence of ad-
verse effects, including tinnitus, dizziness, and vomiting. Low
birth weight was deﬁned as <2500 g, measured within 24 hours
after delivery. Prematurity was deﬁned as a delivery before 37
weeks of gestation.
Meta-Analysis
Two of the 6 included studies had more than 1 comparison
drug. In the study by Mutabingwa et al [14], the 4 arms included
SP, chlorproguanil-dapsone, SP-amodiaquine, and artesunate-
amodiaquine. The SP-only and chlorproguanil-dapsone arms
were excluded from the analysis because these drugs are no lon-
ger recommended for the case management of malaria (SP) or
are no longer available (chlorproguanil-dapsone) [14]. The
study by Kalilani et al [11] included 3 arms: SP, SP-azithromy-
cin, and SP-artesunate, and again the SP-only arm was exclud-
ed. Whenever standard deviations for continuous variables were
not available, these values were calculated using the reported t
test value or the 95% conﬁdence interval (CI) [21]. Data on ef-
ﬁcacy, safety, and tolerability were summarized using forest
plots, and meta-analyses were conducted when 3 or more stud-
ies had this outcome. We used both random effects (DerSimo-
nian and Laird: primary method) and ﬁxed-effects models to
obtain pooled estimates (pooled risk ratios [PRR] or weighted
mean differences and corresponding 95% CI [22]).Heterogene-
ity was evaluated using the τ2 and χ2 test, and I2 was used to
measure the extent of heterogeneity across trials [23]. Data
were analyzed using Stata (version 13). We conducted subgroup
analysis by type of comparison drug (ACT vs quinine or ACT vs
non-ACT) and continent (Asia vs Africa). We performed sen-
sitivity analyses to examine the effect of study quality (high vs
moderate-to-low).
RESULTS
Of the 411 studies identiﬁed, 65 were included for review of the
full text. An additional 23 studies were identiﬁed from a search
of the references of full-text reviews. Of these 88 studies, 6 met
the inclusion criteria: 3 from sub-Saharan Africa (Malawi,
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Tanzania, and Uganda) and 3 from Thailand (Figure 1). The
studies were conducted between 1995 and 2009 (Table 1).
Artemisinin-based combination therapies used in the trials
included artemether-lumefantrine (1 study), meﬂoquine-
artesunate (2 studies), amodiaquine-artesunate (1 study), SP-
artesunate (1 study), and atovaquone-proguanil-artesunate
(1 study; Table 1); duration of regimens were 3 days, except
for 1 study in Thailand where artesunate was given for 5 days
(in combination with meﬂoquine) [9–14]. Comparator drugs
included the following: quinine for 7 days (4 studies: 3 in
Asia, 1 in Africa); SP in combination with azithromycin for 2
days (1 study, Africa); or amodiaquine for 3 days (1 study, Af-
rica; Table 1). A total of 807 women were enrolled; 415 women
received ACTs, 265 received quinine, and the remaining 127
received the other non-ACTs.
Study Quality
All studies were open label; 4 studies reported blinding of the
microscopist [9, 11, 12, 14], but none of the studies reported
whether the person who assessed the newborn was blinded
(Supplementary 1). The quality of 2 studies was assessed as
“low-to-moderate” due to the lack of information on the methods
used for the random sequence generation and/or how allocation
concealment was assured [10, 13], or due to possible reporting
bias [12, 13] or incomplete reporting of outcomes [9, 12, 13].
All doses of treatment were directly observed in all studies.
Characteristics of Study Participants
Most women were enrolled between 20 and 30 weeks gestation
(Table 2). Documented fever ranged from 4% to 100% at enroll-
ment. The mean or median bodyweights in 2 studies from the
Thai-Burmese border and 1 study in Malawi were lower than in
the other studies. Two studies screened for human immunode-
ﬁciency virus (HIV) status; HIV prevalence was 27% in Malawi,
with a potential difference by study arm (21% vs 34%), but not
all participants agreed to be tested [11]. Only 1 of 161 partici-
pants in the study in Tanzania tested positive for HIV [14]. Al-
though HIV status in the study in Uganda was not assessed, this
was likely approximately 8% based on regional HIV data in
pregnant women around that time [9, 24, 25].
Meta-Analysis of Efﬁcacy
The median PCR-adjusted failure rate by days 28 to 63 in the
non-ACT group was 6 (range, 0–37) per 100 women: meta-
analysis showed that the PCR-adjusted failure rates with
ACTs were lower than with non-ACTs, but the difference over-
all was not statistically signiﬁcant (PRR random-effects model
0.41, 95% CI, 0.16–1.05; I2 = 38%, 95% CI, 0%–75%, 6 trials;
Figure 1. PRISMA flow diagram. Abbreviation: ACTs, artemisinin-based combination therapies.
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Table 1. Description of Included Studies Evaluating ACT vs Non-ACT in Pregnancy, Asia and Africa, 1995–2009
Author [Ref.]
Country
(Time Period) Population
Experimental
Treatment (First Arm)
No. of
Women in
First Arm of
the Study
Comparison
Treatment (Other
Arm(s))
No. of
Women in
Other Arm(s)
of the Study
Efficacy
Outcomes
Reporteda
Safety Outcomes
Reported
(in Chronological
Order)
Tolerability
Reported (in
Alphabetical
Order)
Bounyasong
[10]
Thailand
(January
1995–
December
1998)
Pregnant women with a
gestational age of at least
28 wks infected by
Plasmodium falciparum
(<4% of RBC parasitized)
AS5 +MQ1 (2 mg/kg
artesunate p.o. as a
first dose with
subsequent 1 mg/kg
per 12 h p.o. for
5d + 25 mg/kg
mefloquine p.o. on
day 6)b
Patients admitted for
duration of treatment
28 women Q7 (10 mg/kg
quinine sulphate
p.o. t.i.d. for 7 d)
Patients admitted for
duration of
treatment
29 women Treatment failure
Parasite clearance
time
Fever clearance time
Hypoglycemia
Hematocrit
Pregnancy complications
Fetal growth (biparietal
diameter)
Gestational age
(ultrasound, LMP
and fundal height)
Apgar scores; arterial
blood pH
Birthweight within 24 h
Head and abdominal
circumference
Neurological test scores
infant
Neonatal jaundice
(follow-up: 28 d)
Neurological and physical
development up to 24
mo
Blurred vision
Nausea
Palpitations
Tinnitus
Vertigo
Vomiting
(Follow up 28 d)
Kalilani [11] Malawi
(September
2003–
September
2004)
Pregnant women (EGA 14–
26 wks) between 15 and
49 y old, with peripheral P
falciparum parasitemia
AS3 + SP1 (3× 500 mg
sulfadoxine/25 mg
pyrimethamine p.o.
once + 200 mg/day
artesunate p.o. for
3 d)
All doses supervised
47 women SP1 + AZ2 (3× 500
mg sulfadoxine/
25 mg
pyrimethamine p.
o. once + 1 g/day
azithromycin p.o.
for 2 d)
All doses supervised
47 women Treatment failure
Parasite clearance
time
Fever clearance time
Hemoglobin
Pregnancy outcome:
Abortion (<28 wks of
gestation)Stillbirth (>28
wks of gestation)
Birth weight within 24 h
Prematurity (Ballard score
within 24 h)
Neonatal death
Note: women received the
same drug again during
the rest of the
pregnancy
Adverse events
Abdominal pain
Coughing
Diarrhoea
Fever
General body
pain
Headache
Nausea
Skin rash
Vomiting
(follow up: 28 d
after first
dose)
McGready
[13]
Thai-Burmese
border
(October
1995–July
1997)
Pregnant women in their
2nd or 3rd trimester with
a microscopy-confirmed
uncomplicated P
falciparum infection
AS3 +MQ2 (4 mg/kg
per day artesunate p.
o. on day 0, 1, and
2 + 15, respectively;
10 mg/kg mefloquine
p.o. on day 1 and 2)
All doses supervised
66 women Q7 (10 mg/kg
quinine sulphate
p.o. t.i.d. for 7 d)
All doses supervised
42 women Treatment failure
(for P falciparum)
Parasite clearance
Fever clearance
Gametocyte carriage
Other species than
P falciparum
Hematocrit
Pregnancy outcome:
Abortion
Stillbirths
Congenital abnormalities
Birth weight (Salter scale)
Placental weight
Gestational age (Dubowitz
within 3 d)
Neonatal deaths
Infant development up to
12 mo
Anorexia
Dizziness
Headache
Muscle and joint
pain
Tinnitus.
(follow-up: 28 d)
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Table 1 continued.
Author [Ref.]
Country
(Time Period) Population
Experimental
Treatment (First Arm)
No. of
Women in
First Arm of
the Study
Comparison
Treatment (Other
Arm(s))
No. of
Women in
Other Arm(s)
of the Study
Efficacy
Outcomes
Reporteda
Safety Outcomes
Reported
(in Chronological
Order)
Tolerability
Reported (in
Alphabetical
Order)
McGready
[12]
Thai-Burmese
border
(December
2001–July
2003)
Otherwise healthy pregnant
women (14–32 wks) with
their first episode of
uncomplicated P
falciparum or mixed
infection, and hematocrit
≥20%
AS3 +ATP3 (4 mg/kg
per day
artesunate + 20 mg/
kg per day
atovaquone + 8 mg/
kg per day proguanil
p.o. for 3 d)
All doses supervised
39 women Q7 (10 mg/kg
quinine sulphate
p.o. t.i.d. for 7 d)
All doses supervised
42 women PCR-adjusted
cumulative cure
rate
Median time to PCR-
confirmed
parasite
recrudescence
Median time from
admission to a
novel infection
Parasite clearance
Fever clearance
Gametocyte carriage
Other species than P
falciparum
Hematocrit
Pregnancy outcomes:
Abortion (<28 wks)
Stillbirth (>28 wks)
Birth weight within 24 h
Growth parameters
(newborn head, height
and arm circumference)
Gestational age
(ultrasound, fundal
height or Dubowitz)
Congenital abnormalities
Infant follow-up (neonatal
death, growth
parameters,
neurodevelopmental
scores up to 1 y)
Urticaria
Vomiting
Tinnitus
(follow up: 42 d)
Mutabingwa
[14]
Tanzania
(January
2004–
September
2006)
Pregnant women (14–34
wks of gestation) with
mild-moderate, slide
proven, falciparum
malaria under 38 y old
with an uncomplicated
pregnancy
AS3 + AQ3 (10 mg/kg
amodiaquine + 4 mg/
kg artesunate p.o. for
3 d)
All doses supervised
83 women SP1 + AQ3 (3× 500
mg sulfadoxine/
25 mg
pyrimethamine p.
o. once + 10 mg/
kg amodiaquine
for 3 d)
All doses supervised
80 women Parasitological
failure by day 28
Parasitological failure
by day 14
Clinical failure at day
14 and 28
Gametocytes on day
14
Hemoglobin
Stillbirth
Birth weight
Gestational age (Dubowitz
score)
Congenital abnormalities
Perinatal and neonatal
mortality
Abdominal pain
Dermatological
Diarrhoea
Dizziness
Nausea/
vomiting
Respiratory
complaints.
(follow up: 28 d)
Piola [9] Uganda
(October
2006–May
2009)
Women with a viable
pregnancy with an
estimated gestation of 13
wks or longer and a mild-
moderate malaria
infection detected by
microscopy (P falciparum
mixed or monoinfection).
Women were excluded if
they had P falciparum
parasitemia >250 000
parasites/µL or severe
anemia (hemoglobin <7
g/dL)
AM3 + L3 (80 mg
artemether/480 mg
lumefantrine p.o. b.i.
d. for 3 d)
All doses supervised
152 women Q7 (10 mg/kg
quinine sulphate
p.o. t.i.d. for 7 d)
All doses supervised
152 women PCR-corrected
adequate clinical
and
parasitological
response at day
42
PCR-uncorrected
adequate clinical
response on day
42 or delivery
(whichever came
last)
Parasite clearance
Fever clearance
Gametocyte carriage
Other species than P
falciparum
Hemoglobin
Abnormal laboratory
parameters (ALT,
bilirubin, creatinine, full
blood count) Abnormal
QTc interval on ECG
Gestational age
(ultrasound, LMP if >24
wks)
Birthweight
Congenital abnormalities
Perinatal, neonatal, and
infant death
Abdominal pain
Anorexia
Dizziness
Headache
Influenza-like
syndrome
Nausea
Tinnitus
Vomiting
Weakness
(follow up: 42 d)
Abbreviations: ACT, artemisinin-based combination therapy; AQ, amodiaquine; AL, artemether-lumefantrine; ALT, alanine aminotransferase; AS, artesunate; ATP, atovaquone-proguanil; AZ, azithromycin; d, days; ECG, electrocardiography; EGA, estimated
gestational age; MQ, mefloquine; PCR, polymerase chain reaction; p.o, per os; Q, quinine; L, lumefantrine; LMP, last menstrual period; RBC, red blood cells; Ref., reference; SP, sulfadoxine-pyrimethamine; tid, 3 times per day.
a Primary efficacy outcomes are shown in bold type.
b Artesunate doses might have been extended until parasite clearance and clinical improvement in this study.
A
C
T
s
in
P
regnancy
•
O
FID
•
5
Table 2. Characteristics of Participants at Enrolment of Included Studies Evaluating ACT vs Non-ACT in Pregnancy, Asia and Africa, 1995–2009
Study
Age Gestational Age Fever Maternal Weight Gravidity Parasitemia
ACT Non-ACT ACT Non-ACT ACT Non-ACT ACT Non-ACT ACT Non-ACT ACT Non-ACT
Bounyasong [10] Mean 26.1 y,
sd 7.5,
n = 28
Mean 27.2 y,
sd 7.5,
n = 29
Mean
26.7 wks, sd
7.6, n = 28
Mean
27.4 wks, sd
7.6, n = 29
Mean 40.4°
C, sd 0.6,
n = 28
Mean 40.6°
C, sd 0.6,
n = 29
Mean
57.1 kga, sd
4.1, n = 28
Mean
58.7 kga, sd
4.1, n = 29
Mean 2.4, sd
0.6, n = 28
Mean 2.6, sd
0.6, n = 29
Mean1330/200
WBC, sd 209,
n = 28
Mean 1313/200
WBC, sd 209,
n = 29
Kalilani [11] Median 20 y,
IQR 17–24
Median 20 y,
IQR 18–23
Median
22 wks, IQR
20–24
Median 24 wks,
IQR 20–24
>37.5°C: 2
of 49
(4.1%)
>37.5°C: 3
of 49
(6.1%)
Mean 52.9 kg,
sd 5.9,
n = 47
Mean 52.2 kg,
sd 6.1,
n = 47
Median 1, IQR
1–3 PG: 28
of 47
(59.6%)
Median 1, IQR
1–3 PG: 25
of 47
(53.1%)
Geometric mean
687/µL, range
120–4260
Geometric mean
1184/µL, range
150–22 500
McGready [13] Median 24 y,
range
15–37,
n = 66
Median 23 y,
range
16–36,
n = 42
Median
24 wks,
range 12–40,
n = 66
Median 24 wks,
range 15–38,
n = 42
>37.5°C:
10 of 66
(15.2%)
>37.5°C: 9
of 42
(21.4%)
Median 48 kg,
range 36–
68, n = 66
Median 50 kg,
range 41–
67, n = 42
PG: 18 of 66
(27.3%)
PG: 12 of 42
(28.6%)
Median
11 651/µL, range
32–241 127,
n = 66
Median 19 086/
µL, range 79–
149 389, n = 42
McGready [12] Mean 26 y,
sd 6,
n = 39
Mean 26 y,
sd 7,
n = 42
Mean 21 wks,
sd 5.3,
n = 39
Mean 21 wks,
sd 4.5, n = 42
Fever b
7 of 39
(17.9%)
Fever b
7 of 42
(16.7%)
Mean 49 kg,
sd 7, n = 39
Mean 50 kg,
sd 7, n = 42
PG: 12 of 39
(30.8%)
PG: 11 of 42
(26.2%)
Geometric mean
2596/ µL, range
33–123 027
Geometric mean
2084/µL, range
33–109 648
Mutabingwa [14] Median 21 y,
IQR
19–26,
n = 83
Median 20 y,
IQR
19–25,
n = 80
Median 6 mo,
IQR 5–7,
n = 83
Median 7 mo,
IQR 5–7,
n = 80
NR NR NR NR PG: 20 of 34
(59%)
PG: 14 of 38
(37%)
Median181/200
WBC
range 62–628,
n = 83
Median 25/200
WBC
range 51–578,
n = 80
Piola [9] Mean 22.5 y,
range
15–38,
n = 152
Mean 22.6 y,
range
17–38,
n = 152
Mean
22.3 wks,
range 9–38,
n = 152
Mean
24.7 wks,
range 10–39,
n = 152
>37.5°C:
35 of 152
(23.0%)
>37.5°C:
30 of 152
(19.7%)
Mean 58 kg,
sd 10,
n = 152
Mean 58 kg,
sd 10,
n = 152
Median 2,
range 1–8
Median 2,
range 1–7
Geometric mean
1418/µL, sd
4727, n = 152
Geometric mean
1995/µL, sd
9771, n = 152
Abbreviations: ACT, artemisinin-based combination therapy; IQR, interquartile range; kg, kilogram; NR, not reported; PG, primigravidae; sd, standard deviation; WBC, white blood cells.
a Bounyasong [10]: Weight before pregnancy.
b Fever threshold not defined.
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Figure 2. (A) Meta-analysis of PCR-adjusted parasitological treatment failure risk comparing artemisinin-based combination therapies (ACTs) vs. non-ACTs, stratified by
comparator drug. (B) Meta-analysis of PCR-adjusted parasitological treatment failure risk comparing ACTs versus non-ACTs, stratified by geographical region. (Note: Because
statistical programs cannot handle 0% treatment failure for both arms in meta-analysis, information from Bounyasong [10] was entered as 1/28 for each arm, to attain a
balanced risk ratio (RR) of 1 [26].) The shaded areas around the estimates are proportional to the weight of each study in the analysis. Abbreviations: AM, artemether;
AQ, amodiaquine; AS, artesunate; ATP, atovaquone-proguanil; AZ, azithromycin; CD, chlorproguanil-dapsone; CI, confidence interval; L, lumefantrine; MQ, mefloquine; Q, qui-
nine; SP, sulfadoxine-pyrimethamine.
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Figure 2A). Subgroup analysis by comparator drug showed that
ACTs were signiﬁcantly more effective than oral quinine and re-
duced the risk of treatment failure by 80% with no heterogeneity
between trials (PRR 0.20, 95% CI, 0.08–0.49; I2 = 0%, 95% CI,
0%–85%, 4 studies; Figure 2A). Analysis by continent showed
signiﬁcantly lower failure rates with ACTs than non-ACTs in
Thailand (PRR 0.19; 95% CI, 0.07–0.49), but not in Africa
(PRR 0.87; 95% CI, 0.30–2.51; Figure 2B). Artemisinin-based
combination therapies were associated with ≥95% cure rates
in 5 of the 6 studies; the exception was the SP-artesunate arm
in the study from Malawi, which had a cure rate of 92% after
42 days (Figure 3). The parasite clearance rates were signiﬁ-
cantly faster with ACTs than with quinine (Supplementary
Table 2.1) [9, 10, 12, 13] with a lower risk of being positive by
day 2 (PRR 0.23, 95% CI, 0.11–0.45; I2 = 50%, 3 studies). Results
of other efﬁcacy outcomes that were not combined by meta-
analysis because of differences between studies in units of mea-
sure (eg, hemoglobin vs hematocrit) or time points are given in
Supplementary 2; these include hemoglobin, fever clearance,
effect on gametocytes, other species than P falciparum and in-
fant follow up. Gametocyte carriage overall was signiﬁcantly
lower in the ACT groups compared with quinine in 2 studies
in Thailand, and in the study in Uganda gametocyte clearance
was faster in the ACT group compared with quinine (Supple-
mentary Table 2.2) [9, 12, 13].
Meta-Analysis of Birth Outcomes
Mean birth weight was signiﬁcantly higher in children born to
ACTs recipients compared with non-ACTs recipients (mean
weighted difference 75 g, 95% CI, 3–148 g; I2 = 6%, 95% CI,
0%–76%, 6 studies; Figure 4). The prevalence of low birth
weight was not different (PRR 0.98, 95% CI, 0.62–1.54;
I2 = 0%, 4 studies; Figure 5), and neither were the estimated
mean gestational age (mean weighted difference 0.11 weeks,
95% CI, −0.26 to 0.48 weeks, I2 = 0%, 4 studies, all ACT vs qui-
nine) or the prevalence of preterm births (PRR 0.69, 95% CI,
0.38–1.27; I2 = 0%, 2 studies; Figure 5). The occurrence of
fetal loss (ACTs: 15 of 385 [3.9%], non-ACTs: 13 of 364
Figure 3. Polymerase chain reaction (PCR)-adjusted cure rates (proportions) after treatment with artemisinin-based combination therapies (ACTs) and non-ACTs for uncom-
plicated malaria in pregnancy. The number after the drug indicates the number of days the drug was given. The red dashed vertical bar indicates the 0.95 proportion mark, which
is the cut-off recommended by the World Health Organization (WHO) as the minimum efficacy for antimalarial medicines to be adopted as part of national malaria programs
[27]. Abbreviations: AM, artemether; AQ, amodiaquine; AS, artesunate; ATP, atovaquone-proguanil; AZ, azithromycin; CI, confidence interval; L, lumefantrine; MQ, mefloquine;
Q, quinine; SP, sulfadoxine-pyrimethamine.
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[3.6%], PRR 1.04, 95% CI, 0.49–2.20; I2 = 0%, 5 studies;
Figure 5) and congenital abnormalities detected at birth were
not signiﬁcantly different (ACTs: 4 of 377 [1.1%], non-ACTs:
3 of 356 [0.8%], PRR 1.38, 95% CI, 0.31–6.08; I2 = 0%, 3 studies;
Figure 5). Three studies (all in Thailand) observed infants
for more than 5 months and reported an absence of develop-
mental differences by treatment arm (Supplementary Table 2.3)
[10, 12, 13].
Meta-Analysis of Tolerability
A lower prevalence of tinnitus, dizziness, and vomiting was re-
ported among women using ACTs compared with women
using quinine, and this result was statistically signiﬁcant for diz-
ziness and vomiting (tinnitus PRR 0.19, 95% CI, 0.03–1.11, 4
studies; dizziness PRR 0.64, 95% CI, 0.44–0.93, 3 studies, vom-
iting PRR 0.33, 95% CI, 0.15–0.73, 2 studies [1 study zero
events]; Figure 5). Only 1 of the 4 studies that used quinine re-
ported on hypoglycemia, with a signiﬁcantly higher proportion
in the quinine arm compared with ACT (quinine 21 of 29,
72.4%, vs ACT 3 of 28, 10.7%, risk ratio [RR] 6.76, 95% CI,
2.27–20.15, P < .01) [10].
DISCUSSION
In our meta-analyses, ACTs were better tolerated and much
more effective than oral quinine for the treatment of uncompli-
cated falciparum malaria in pregnancy, and they were associat-
ed with faster asexual and sexual parasite clearance and lower
PCR-corrected treatment failures and less gametocyte carriage.
No differences were seen in the risk of fetal death or congenital
abnormalities, although the number of events was low and the
power to detect differences was limited.
Across all studies, treatment with ACTs was associated with a
consistently higher mean birth weights (75 grams) relative to
the non-ACT recipients. The size of the effect on birth weight
is remarkable given the variety in timing of treatments by ges-
tation across pregnancy. Artemisinin-based combination thera-
pies may be more effective in providing radical cure and
clearing parasites from the placenta than non-ACTs, as suggest-
ed by the trial in Uganda, which showed a lower prevalence of
placental hemozoin deposition in the ACT arm compared with
women who received quinine [29]. Alternative explanations in-
clude a chance ﬁnding, given that there was no difference in the
Figure 4. Mean birth weight (grams) of newborns born to artemisinin-based combination therapy (ACT) and non-ACT recipients. (Note: All participants in the study by
Kalilani et al [11] received the same treatment again at least 4 weeks after the first treatment, regardless of whether they were parasitemic at that subsequent visit.)
The shaded areas around the estimates are proportional to the weight of each study in the analysis. Abbreviations: AM, artemether; AQ, amodiaquine; AS, artesunate;
ATP, atovaquone-proguanil; AZ, azithromycin; CD, chlorproguanil-dapsone; CI, confidence interval; L, lumefantrine; MQ, mefloquine; N, sample size; Q, quinine; SD, standard
deviation; SP, sulfadoxine-pyrimethamine.
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frequency of low birth weight, or observer bias due to the ab-
sence of blinding among staff who weighed newborns.
A difference was noted in efﬁcacy by geographical region. The
studies in Asia were conducted in the same region in Thailand
using the same comparator drug (quinine), and this will have
added to the more uniform results in Asia, whereas the studies
in Africa were conducted in 3 different countries (with different
malaria epidemiology) with 3 different ACTs and comparator
drugs, which will have added to the variability in results in Africa.
A review of artemisinin use in pregnancy conducted in 2007
concluded that ACTs have an excellent efﬁcacy proﬁle in the
second and third trimester, but researchers also stressed the im-
portance of more research into the safety of ACTs in pregnancy
[30].The current review adds to this limited database and shows
that the risk of congenital abnormalities and fetal death (spon-
taneous miscarriage or stillbirth) is similar among women with
acute malaria treated with ACTs or other antimalarials when
used for the case management of uncomplicated malaria in
the second and third trimester (Figure 4).
Artemisinin-based combination therapies were much better
tolerated than the comparison drugs, in particular quinine,
which is associated with the symptom complex of cinchonism,
which combined with the fact that it has to be taken 3 times
daily for 7 days is a major determinant of the low adherence
to the quinine regimen [5, 31]. This was illustrated in one of
the included studies from Uganda where quinine recipients
were more likely to stop their treatment prematurely (6 of 152
or 3.9%) than artemether-lumefantrine recipients (1 of 152 or
0.7%, P = .06) [9]. Hypoglycemia is a well known side-effect of
quinine therapy, especially when given parenterally in patients
with severe disease; 1 of the 4 studies using oral quinine mon-
itored for hypoglycemia [32] and found a higher risk in the qui-
nine arm (RR 6.76, 95% CI, 2.27–20.15, P < .01) [10].
This review is subject to several limitations, which may
inform the design and conduct of future studies. First, the 6 in-
cluded studies were heterogeneous in study design with regards
to treatment regimen, outcomes, and population. Each study
used a different ACT, and the timing of the measurement of
the primary efﬁcacy endpoint, the PCR-adjusted failure rate,
varied from day 28 to 63; none of the studies was blinded. Tol-
erability indicators varied between studies as well as the meth-
ods and timing of assessment of many of the secondary efﬁcacy
measures, making it difﬁcult to pool the information. The small
number of studies limited the ability to explore determinants of
Figure 5. Other efficacy, safety, and tolerability outcomes and subgroup analyses by control drug. The Assumed control-group risk (ACR) represents the observed median risk
(expressed per 100 women) and range for each subgroup in the control-drug arm. The range for the ACR is only provided to illustrate high‐ and low‐risk populations, whereas the
median risk is illustrative of a population with a moderate risk. The Corresponding intervention-group risk ([CIR] 95% confidence interval [CI]) is the corresponding risk in the ACT
group computed as the ACR × risk ratio ([RR] 95% CI) [28]. Heterogeneity relating to the extent that the RRs vary between subgroups are shown as the I2 statistic, which depicts
the percentage of the between‐study or between subgroup heterogeneity that is attributable to variability in the effect, rather than sampling variation. The corresponding P
value is based on the χ2 statistic. *The number in brackets depicts the number of studies that were excluded in the analysis because of 0 events in both arms. †Heterogeneity
between subgroups (quinine vs other non-ACT as control drug): low birth weight I2 0%, P = .89; miscarriage or stillbirth I2 0%, P = .39; congenital abnormalities I2 0%, P = .48.
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the heterogeneity that was observed (such as effect of HIV in-
fection, differences in mean maternal weight, or time trends)
and the evaluation of rarer adverse events. All 3 studies in
Asia were conducted on the Western border of Thailand with
Myanmar, which may limit the generalizability of the results.
Three studies were conducted in countries where intermittent
preventive treatment with SP was the national policy at the
time of the study. In one study, the same case-management
drug regimen was repeated after at least 4 weeks as an alternative
to intermittent preventive treatment with SP [11]; in another
study, it was reported that women did not receive intermittent
preventive treatment when they participated in the study [9],
whereas in the last study women were treated according to
the National Tanzanian policy and could have received SP dur-
ing follow up [14]. The design of a standardized protocol for the
assessment of the efﬁcacy and safety of antimalarials for the case
management of malaria in pregnancy would help to reduce
some of these limitations in future trials.
CONCLUSIONS
In summary, this meta-analysis suggests that 3-day ACT regi-
mens are more effective and better tolerated than 7 days of
oral quinine for the treatment of uncomplicated P falciparum
malaria in the second and third trimester of pregnancy. Artemi-
sinin-based combination therapies should be the preferred
treatment option for uncomplicated malaria in second and
third trimester of pregnancy, and countries should make sure
this treatment policy is adhered to by health workers [5].
Supplementary Material
Supplementary material is available online at Open Forum Infectious Dis-
eases (http://OpenForumInfectiousDiseases.oxfordjournals.org/).
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